- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02935075
Optimization of Antiretroviral Therapy (OAT)
February 16, 2020 updated by: Hongzhou Lu, Shanghai Public Health Clinical Center
The combination antiretroviral therapy (cART) inhibit HIV replication effectively.
However, synergy among these drugs has not been well considered.
The dose of drugs used as monotherapy is the same as that used in combination therapy.
Tenofovir+lamivudine+efavirenz is still the first line regimen of cART in developing countries.
The side effects of these drugs are related to the concentration of drugs.
Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
184
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210003
- The Second Hospital of Nanjing
-
-
Shanghai
-
Shanghai, Shanghai, China, 201508
- Shanghai Public Health Clinical Center
-
-
Yunnan
-
Kunming, Yunnan, China, 650041
- Yunnan AIDS Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV antibody positive
- Chinese nationality
- Naïve to antiretroviral therapy
- Willing to start antiretroviral therapy
- Provision of written informed consent
Exclusion Criteria:
- Pregnant, breastfeeding, or lactating
- Females try to get pregnant during the research period
- Subjects who allergic to any of the research drugs
- Subjects that taking other drugs that known to impact the absorption, distribution, metabolism and excretion of the research drugs
- Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. This would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy
- Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
- Laboratory blood values:
- Haemoglobin <9.0 grams/decilitre (g/dL)
- Neutrophil count <1500/mm3
- Platelet count <75,000/mm3
- Aspartate aminotransferase or Alanine transaminase >3 times Upper Limit of Normal (ULN)
- Total bilirubin >3 times Upper Limit of Normal (ULN)
- Subjects with an estimated creatinine clearance of <90 mL/minute
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reduced dose
Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
|
Oral daily
Oral daily
Oral daily
|
Active Comparator: Standard dose
Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
|
Oral daily
Oral daily
Oral daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with HIV viral road < 50 copies/ml
Time Frame: 48 weeks
|
calculate the percentage of patients who with HIV viral road <50 copies/ml every month in two groups
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cell Differentiation 4 (CD4) T cell counts
Time Frame: 48 weeks
|
48 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of adverse events
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Hongzhou Lu, Shanghai Public Health Clinical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 5, 2018
Primary Completion (Actual)
June 5, 2019
Study Completion (Actual)
August 31, 2019
Study Registration Dates
First Submitted
October 14, 2016
First Submitted That Met QC Criteria
October 14, 2016
First Posted (Estimate)
October 17, 2016
Study Record Updates
Last Update Posted (Actual)
February 18, 2020
Last Update Submitted That Met QC Criteria
February 16, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Tenofovir
- Lamivudine
- Efavirenz
Other Study ID Numbers
- 2016-M-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Tenofovir disoproxil fumarate
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
University of HawaiiGilead SciencesUnknown
-
Gilead SciencesCompletedChronic Hepatitis BUnited States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis BChina
-
University of KwaZuluMedical Research Council, South Africa; Centre for the AIDS Programme of Research...Completed
-
University of ManitobaWorld Health Organization; DMSC; Ashodaya SamithiCompleted